This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Plaqenil Role in Prevention of Age Related Macular Degeneration

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2012 by Ziv Hospital.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Ziv Hospital Identifier:
First received: February 2, 2012
Last updated: February 29, 2012
Last verified: January 2012
The investigators think that there is a connection between the use of plaquenil and the prevention of Age related macular degeneration (AMD). The investigators believe that the use of plaquenil makes bruch's membrane thicker, thereby preventing Chroidal Neovascularization (CNV) growth.

Age Related Macular Degeneration

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Observational Study Between People That Use Plaquenil and Those Who do Not in Prevention of AMD.

Resource links provided by NLM:

Further study details as provided by Ziv Hospital:

Estimated Enrollment: 30
Study Start Date: January 2012
Estimated Study Completion Date: April 2012
RA patients treated with plaquenil
Patients who do not use plaquenil

Detailed Description:
the study is done by comparing to groups RA patients who take plaquenil Vs. group of patients who do not take plaquenil. after measuring the retina thickness we compare the avg. thickness of both groups.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Ziv Medical center retina clinic population

Inclusion Criteria:

  • all people who suffer from rheumatoid arthritis (RA) and use plaquenil

Exclusion Criteria:

  • patients who did not complete follow-up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01541449

Contact: Joseph Pikkel, M.D 0508434206

Ziv Medical Center Recruiting
Safed, Israel, 13100
Contact: Otzem Chassid, M.D    0506266059   
Sponsors and Collaborators
Ziv Hospital
Principal Investigator: Joseph pikkel, M.D Ziv Medical Center
  More Information

Responsible Party: Ziv Hospital Identifier: NCT01541449     History of Changes
Other Study ID Numbers: ZIV-0061-11
Study First Received: February 2, 2012
Last Updated: February 29, 2012

Keywords provided by Ziv Hospital:

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents processed this record on August 18, 2017